Travere TherapeuticsTVTX
TVTX
About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Employees: 385
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 28
43% more capital invested
Capital invested by funds: $1.16B [Q3] → $1.66B (+$499M) [Q4]
40% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 53
39% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $16.2M
11% more funds holding
Funds holding: 176 [Q3] → 195 (+19) [Q4]
2.65% more ownership
Funds ownership: 108.07% [Q3] → 110.72% (+2.65%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$31
108%
upside
Avg. target
$40
169%
upside
High target
$47
215%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Vamil Divan 34% 1-year accuracy 10 / 29 met price target | 215%upside $47 | Buy Reiterated | 14 Apr 2025 |
Canaccord Genuity Edward Nash 58% 1-year accuracy 11 / 19 met price target | 215%upside $47 | Buy Maintained | 10 Apr 2025 |
B of A Securities Greg Harrison 24% 1-year accuracy 10 / 41 met price target | 108%upside $31 | Buy Maintained | 1 Apr 2025 |
JP Morgan Anupam Rama 15% 1-year accuracy 9 / 61 met price target | 195%upside $44 | Overweight Maintained | 26 Feb 2025 |
Citigroup Carly Kenselaar 67% 1-year accuracy 2 / 3 met price target | 135%upside $35 | Buy Maintained | 24 Feb 2025 |
Financial journalist opinion
Based on 3 articles about TVTX published over the past 30 days
Neutral
Business Wire
1 week ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.
Neutral
Business Wire
2 weeks ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS.
Positive
Investors Business Daily
3 weeks ago
Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles
The stock market is attempting to rebound amid President Donald Trump's trade war. The post Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
1 month ago
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, two of the largest head-to-head interventional studies conducted to date in adult and pediatric patients with FSGS.
Neutral
GlobeNewsWire
1 month ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 41,200 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March:
Neutral
Seeking Alpha
1 month ago
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Yigal Nochomovitz - Citigroup Prakhar Agrawal - Cantor Fitzgerald Fadi Ahman - Wells Fargo Gregory Harrison - Scotiabank Jason Zemansky - BofA Securities Alexander Thompson - Stifel Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
1 month ago
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI ® (sparsentan) for FSGS
Charts implemented using Lightweight Charts™